Headache and Migraine

The director of headache medicine and chief of general neurology at Yale Medicine spoke about the significance of having CGRP inhibitors in migraine treatment, and how eptinezumab fits into the treatment landscape.

No differences were observed in the magnitude of ubrogepant treatment effect between defined triptan subgroups.

The clinical professor of neurology at Albert Einstein College of Medicine spoke about the trends revealed by the OVERCOME study, and how this data can be used to improve the management of the millions of patients with migraine in the US.

The director of the Montefiore Headache Center and professor of neurology at Albert Einstein College of Medicine spoke about the results of an analysis of eptinezumab’s effect on the severity of migraine and its impact on patients’ lives.

Atogepant significantly reduced mean monthly migraine days compared to placebo across a number of doses and was generally well-tolerated, with no treatment-related serious adverse events.

Real-world data of erenumab indicates that a large number of patients are the chronic migraine population, and there is a high rate of persistence to the anti-CGRP therapy. The most commonly prescribed dose of erenumab was 70 mg.

Patients with migraine who reported both moderate and severe pain intensity during headache attacks experienced high rates of relief and freedom from pain and their most bothersome symptom when treated with 3-mg sumatriptan injection, DFN-11.

An analysis of the open-label PREVAIL trial demonstrated a magnitude of therapeutic effect for eptinezumab that was either maintained or improved with subsequent infusions.

The professor of neurology, neurotherapeutics, and ophthalmology at UT Southwestern spoke about the potential of telemedicine in headache medicine, as well as the findings from a single-center, 45-patient study.

Despite ongoing discussion regarding the 6-item Headache Impact Test’s relevance in the migraine population—for which it was not specifically developed—the test has been shown to be a useful tool in the assessment of patients with migraine.

The director of the MedStar Georgetown Headache Center spoke about ubrogepant’s long-term safety and efficacy and its potential to fill the large gap that remains in acute migraine care.

Patients with migraine rated their telemedicine visits as more convenient with shorter visit times; two factors that can also benefit providers.

Survey data revealed 36% of patients with migraine with prescription medications were using opioids in acute management, though data also reinforced that receiving a diagnosis of migraine or chronic migraine was associated with a significantly decreased likelihood of opioid use.

As measured with the Migraine Disability Assessment, the proportion of patients with episodic migraine experiencing severe disability was reduced significantly, and Headache Disability Inventory scores were significantly reduced.

Almost 20% of rimegepant-treated patients experienced pain freedom within 2 hours of receiving a 75-mg dose compared to the placebo group, in which 12% were pain-free at 2 hours.

Both the frequency of headache days and the intake of acute medication were decreased with the use of a daily, single 20-minute eTNS session over the course of 3 months in an open-label, monocenter, prospective pilot trial.

Stephen D. Silberstein, MD, past AHS president and Editor in Chief of NeurologyLive, provides a preview of premier sessions that will take place at the upcoming annual meeting.

Physicians should ask patients about their history of headaches and monitor for possible indicators of stroke, especially among older individuals who are already at increased risk.

Food insecurity and migraine, anxiety sensitivity and migraine severity, supraorbital stimulation to prevent chronic migraine-find summaries of these and other recent findings here.

The neurological symptoms of migraine aura are generally attributed to cortical spreading depression/depolarization, although that hypothesis does have its detractors. The question of whether CSD triggers migraine headache remains controversial.

The staff neurologist at Cleveland Clinic’s Mellen Center for MS shared her insight into the use of telemedicine in an outpatient setting across a number of subspecialties in neurology and how it can supplement care going forward.

The professor of neurology at both the University of California San Francisco and King’s College, London, spoke about the results from a phase 2b/3 study evaluating atogepant for prevention of migraine.

Neurology News Network for the week ending June 8, 2019.